Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor
10. Juli 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, July 10, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Appoints Anshul Thakral as Non-Executive Director of the Board
08. Juni 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, June 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Present at the Jefferies 2023 Healthcare Conference
25. Mai 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, May 25, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market
17. Mai 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, May 17, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea To Present at the JMP Securities Life Sciences Conference
08. Mai 2023 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ
28. April 2023 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Receives A$8.7 million R&D Tax Incentive
07. März 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, March 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare Conference
06. März 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, March 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology
13. Februar 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea To Present at SVB Leerink Global Biopharma Conference
06. Februar 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...